Estimating the case fatality ratio of the COVID-19 epidemic in China

Xing Wang[1,2]* PhD, Zihui Ma[1]* MS, Yi Ning[3,4]* ScD MPH MD, Chen Chen[1,5] PhD, Rujin Chen[6] MD, Qiwen Chen[7] MD PhD, Heng Zhang[1] PhD, Chunming Li[1] MS, Yan He[1] MD, Tao Wang[1] MCS, Cheng Tong[1] MD, Junqing Wu[8] PhD, Yuyan Li[8] PhD, Handong Ma[1,9]** PhD, Shaodian Zhang[1]** PhD, Hongxin Zhao[1]** MD PhD

1. Shanghai Synyi Medical Technology Co, Ltd, Shanghai, China

2. NHC Key Laboratory of Reproduction Regulation (Shanghai Institute of Planned Parenthood Research), Public Health School, Fudan University, Shanghai, China

3. Meinian Institute of Health, Beijing, China

4. Peking University Health Science Center Meinian Public Health Research Institute, Beijing, China

5. National Institute of Environmental and Health, Chinese Center for Disease Control and Prevention, Bejing 100050, China

6. Donor Service, Shanghai Blood Center, Shanghai, China

7. Department of Integrative Oncology, Shanghai Cancer Center, Shanghai Medical School, Fudan University, Shanghai, China

8. NHC Key Laboratory of Reproduction Regulation (Shanghai Institute of Planned Parenthood Research), Fudan University, Shanghai, China

9. Department of Computer Science, Shanghai Jiao Tong University, Shanghai, China

* Xing Wang, Zihui Ma, and Yi Ning contributed equally to the article.

** Corresponding Authors:
Hongxin Zhao, Handong Ma, and Shaodian Zhang. Shanghai Synyi Medical Technology Co, Ltd, 5th Floor, 232 Liangjing Road, Shanghai 201206, China.
Emails: zhx@zhaohx.com; handong@synyi.com; shaodian@synyi.com

Abstract

Background: Corona Virus Disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan city and rapidly spread throughout China since late December 2019. Crude case fatality ratio (CFR) with dividing the number of known deaths by the number of confirmed cases does not represent the true CFR and might be off by orders of magnitude. We aim to provide a precise estimate of the CFR of COVID-19 using statistical models at the early stage of the epidemic.

Methods: We extracted data from the daily released epidemic report published by the National Health Commission P. R. China from 20 Jan 2020, to 11 Feb 2020. Competing risk model were used to obtain the cumulative hazards for death, cure, and cure-death hazard ratio. Then the CFR estimation was calculated based on the slope of the last piece in joinpoint regression model, which reflected the most recent trend of the epidemic. Sensitivity analyses were performed by assuming an average period of observation stays for 3-7 days after recovery.

Results: As of 11 Feb 2020, totally 44,653 cases were diagnosed as COVID-19 in mainland China. Assuming an average period of 5 days' observation stays after severe cases turned to be asymptotic, adjusted CFR of COVID-19 were 14.97% (95% CI: 14.22%-15.77%) in Hubei province, including Wuhan, the epicenter, and 0.52% (95% CI: 0.42%-0.71%) in other areas of China, respectively. We observed obvious decreasing trends of adjusted CFR for COVID-19, with two distinct turning points on January 26 and February 1 for Hubei province, and one turning point on January 28 for other areas, respectively.

Conclusions: Based on analyses of public data, we found that the CFR in Hubei was

much higher than that of other regions in China. The CFR would follow a downwards trend based on our estimation and recently released data. Nevertheless, at early stage of outbreak, CFR estimates should be viewed cautiously because of limited data source on true onset and recovery time.

Keywords: COVID-19; SARS-CoV-2; case fatality ratio; competing risks; Hubei

Introduction

On December 8, 2019, the first pneumonia cases with unknown etiology was identified in Wuhan city, Hubei province, China [1]. Subsequently, World Health Organization (WHO) appointed an expert group arrived in China to guide the epidemic management. On January 8, 2020, the pathogen of this unexplained infected pneumonia was isolated by Chinese researchers, now known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [2-4], which resembled to the severe acute respiratory syndrome coronavirus (SARS-CoV) [1]. On January 25, 2020, WHO released the Novel Coronavirus (2019-nCoV) situation report-5 and stated that the new coronavirus epidemic has posed a very high risk to China and a high risk to both regional level and global level [5]. On February 11, 2020, WHO officially named this disease caused by the new coronavirus SARS-CoV-2 as COVID-19 [6]. As of February 11, 2020, a total of 44,653 confirmed cases and 1,114 death cases with COVID-19 infection were reported from 31 provinces (autonomous regions,

municipalities) in China [2].

To date, in the first month since identification of the COVID-19 (Jan 8th-Feb 11th, 2020), considerable new knowledge about this coronavirus have been generated, such as person-to-person transmission [7], clinical characteristic [8-10], prediction on the incubation period, basic reproductive number, total case number, and epidemic trend [11, 12]. However, key question about the CFR, an important epidemiological indicator for reflecting and predicting the severity of the disease, of the COVID-19 epidemic remains unsolved. Timely and accurate estimates of the CFR are critical for predicting the outbreak dynamics and health care capacity needed, to tailor appropriate and effective measures for disease control, public safety, and allocation of health resources.

At the early stage of COVID-19 outbreaks, given the limited and incomplete data (for the epidemic is still ongoing), the CFR is a crude estimated as by dividing the number of known deaths by the number of confirmed cases with COVID-19 in previous papers [8-10]. Nevertheless, these results are subject to large errors because future deaths are not taken into account, instead, which might be off by orders of magnitude. Diagnosis of viral infection will develop to two competing risk outcomes, recovery or death, by days to weeks and the denominator of CFR, the number of confirmed cases, at the cross-sectional level should consider the loss of those recovered [13]. Hence in this study we aim to provide a precise estimate of the case fatality ratio of COVID-19 epidemic at present.

Methods

Data sources

We extracted the daily released epidemic report published by the National Health Commission P. R. China from 20 Jan, 2020, to 11 Feb, 2020 [14]. For each day, the number of new admissions, cumulative number of cases, number of new deaths, cumulative number of deaths, newly cured patients, and cumulative number of cured patients were obtained.

Statistical analysis

Although it did not include any individual patient data, the CFR estimated using the competing risks model in the survival analysis [15]. Following the standard non-parametric competing risks theory, the daily hazards for dying and cure, treated as competing risks, are each estimated, and the other endpoint are treated as censoring.

For each day i, we captured the number of new admissions (n_i), cumulative number of cases (N_i), number of new deaths (d_i), cumulative number of deaths (D_i), newly cured patients (c_i), and cumulative number of cured patients (C_i).

Other parameters listed below:

t: the survival time during the admission-to-cure or death;

J: 1denoted for death, 2 denoted for cure;

λ: 1 denoted for the daily hazards for dying, 2 denoted for the daily hazards for curing, other endpoints are censored;

m_i: equaled to $N_i - D_i - C_i$, denoted for the number of patients in hospital;

a_i: equaled to $(m_{i-1} + m_i)/2$, denoted for the average number of patients in hospital (at risk) for each day I;

λ_{i1}, equaled to d_i/a_i, denoted for the daily hazards for death;

λ_{i2}, equaled to c_i/a_i, denoted for the daily hazards for cure;

$\Lambda_1(k)$, equaled to $\sum_{i=1}^{k} \lambda_{i1}$, denoted for the cumulative hazards for death up to k days; $\Lambda_2(k)$, equaled to $\sum_{i=1}^{k} \lambda_{i2}$, denoted for the cumulative hazards for cure up to k days;

θ_k, equaled to $\Lambda_{k2}/\Lambda_{k1}$, denoted for the cure-death hazard ratio for each day k.

$P(J)$, J=1denoted for the ultimate case fatality ratio, J=1denoted for the ultimate case cure rate.

For up to day k, the cumulative hazards for death, cure, and cure-death hazard ratio were obtain. If the ratio is constant θ over the study period, then it follows that $P(J=1)=\theta P(J=2)$. Since $P(J=1)+P(J=2)=1$, we $P(J=1)=1/(1+\theta)$. Therefore, if the ratio is a constant θ during a period then the ultimate CFR in that period is defined as $1/(1+\theta)$. To investigate the relationship between cure-death hazards was linear or non-linear, the cure-death hazard plot was shown. If non-linear relationship was discovered, joinpoint regression will be used [16].

Actually, stringent patient discharge standards have been implemented in hospitals, patients usually need to stay in hospital asymptotically for 3-7 days, therefore, the published cure patients were cured nearly 3-7 days ago. Sensitivity analyses were performed by assuming an average period of observation stays for 3, 5 and 7 days after recovery, respectively, and the date of cure were accordingly moved backward.

Results

Data description

As of February 11, 2020, it is reported that 44,653 people were diagnosed as COVID-19. Total number of death cases and cured cases of COVID-19 were 1,068 and 2,639 in Hubei province, and 45 and 2,101 in other provinces in China, respectively. The number of deaths and cures in Hubei, including Wuhan, accounted for 96.0% and 56.6% of the whole country, but the proportion of deaths and cures was quite different, which reminded us to separate the fatality rate of Hubei and other areas (Fig.1, 2).

Unadjusted CFR estimation of the COVID-19

In the joinpoint regression, the relationship between cure-death hazards were nonlinear for both Hubei and other provinces (Fig.3 and 4). With the slope (cumulative cured hazard/cumulative death hazard) of joinpoint fitting increased, the corresponding CFR estimation gradually decreased. Specifically, we observed

obvious decreasing trends of CFR for COVID-19, with three great turning points on January 27, February 1, and February 6 for Hubei province, and one turning point on January 29 for other areas, respectively. The dates of slope change and dates for recent CFR estimation in yellow were shown in table 1. Our CFR estimation was calculated based on the slope of the last piece in joinpoint regression model, which reflected the most recent trend of the epidemic. As shown in table 2, unadjusted CFR was estimated to be 19.61% (95% CI: 18.94%-20.33%) in Hubei, and 1.88% (95% CI: 1.73%-2.06%) in other provinces.

CFR adjustment and sensitivity analyses

Nonlinear relationships of cure-death hazards were also obtained for both Hubei and other provinces with moving the date of cure backward for 3, 5, 7 days (Fig.5 and 6). As shown in table 2, adjusted CFR of COVID-19 assuming an average period of observation stays for 3, 5 and 7 days after recovery were 16.23% (95% CI: 15.63%-16.86%), 14.97% (95% CI: 14.22%-15.77%), and 12.72% (95% CI: 12.48%-12.97%) in Hubei province, and 1.08% (95% CI: 0.89%-1.34%), 0.52% (95% CI: 0.42%-0.71%), and 0.32% (95% CI: 0.25%-0.48%) in other provinces of China, respectively.

According to the discharge criteria of the fifth edition of the diagnosis and treatment plan for COVID-19 in China [17], the patients cannot be discharged until 3 consecutive days of thermal withdrawal, improved clinical symptoms, and 2 consecutive times of negative nucleic acid testing. We considered that the adjusted CFR of COVID-19 with an average period of observation stay for 5 days after

recovery would be the most reasonable and down-to-earth. We also observed obvious decreasing trends of 5 days adjusted CFR for COVID-19, with two distinct turning points on January 26 and February 1 for Hubei province, and one turning point on January 28 for other areas, respectively (Fig. 7).

Discussion

Based on public available daily data, we found that the 5 days adjusted CFR of COVID-19 were 14.97% (95% CI: 14.22%-15.77%) in Hubei province, including Wuhan, the epicenter, and 0.52% (95% CI: 0.42%-0.71%) in other areas of China, respectively.

Our estimate of the CFR of 14.97% in Hubei for COVID-19 is between that of SARS-CoV (9.2%) and that of MERS-CoV (34.4%) [18]. Consistent with our results, WHO Collaborating Centre for Infectious Disease Modelling and MRC Centre for Global Infectious Disease Analysis published their 4th edition Report: Severity of 2019-novel coronavirus (nCoV), which showed the estimate the CFR to be 18% (95% CI: 11%-81%) for cases detected in Hubei [19]. However, Chinese researchers Zhong et al. reported a markedly lower CFR (1.4%) among 1,099 patients from 552 hospitals in 31 provinces/provincial municipalities, as compared with that of 15% among 41 patients in Wuhan [10], 11% among 99 patients in Wuhan Jinyintan Hospital [9] , and 4.3% among 138 patients in Wuhan Zhongnan Hospital [8]. However, it should be noted that these CFR estimates were cross-sectional, which were calculated by dividing the number of known deaths by the number of confirmed cases at certain

time point[20].

This estimated CFR of COVID-19 was much higher in Hubei Province than that of other area in China. Several possible reasons could be able to explain this discrepancy. Firstly, high proportion of severe cases among the confirmed patients potentially contributes to high proportion of death in Hubei Province [8-10]. Patients with serious symptoms were prioritized to be admitted to the hospital. Secondly, insufficient medical resources including clinicians, nurses as well as facilities, including diagnosis toolkits at the outbreak of COVID-19 in Hubei directly resulted the deterioration of disease course. It is reasonable to assume that huge amount of mild cases or early-stage cases have developed into more serious conditions before they were able to be admitted and appropriately treated. Thirdly, under-detection of mild or asymptomatic cases also resulted in higher CFR, which may be further aggravated after the outbreak, due to that the daily capacity of virus testing in Hubei has already reached the limit. Fourthly, as the COVID-19 initially outbroke in Wuhan, Hubei, other regions of China and foreign countries gained critical time to develop epidemic control strategy and reallocate medical resources. However, this delay of epidemic in other regions and foreign countries may also result in the delay of fatal cases arising and reporting, which rendered the lower CFR in other regions of China comparing with Hubei Province.

We observed obvious decreasing trends of CFR for COVID-19, with distinct turning points for in Hubei and other areas respectively. From Jan 23, 2020, several unprecedentedly strict and effective measures were carried out, especially the

lockdown of Wuhan, Hubei, including suspended public transportation, forbidden pubic gathering, postponed school and enterprise opening, and furnished kinds of medical resources to prevent further disease transmission [21]. Based on our estimation and recently released data, we concluded that the CFR would follow a downwards trend.

We conducted several sensitivity analyses to reduce bias from time delaying for the observation windows from cure to report. Actually, the time between disease cure and report as well as the extent of underreporting varied over time, cities and countries [13]. In fact, in order to break the capacity limit of virus lab testing and achieve a better control of this epidemic, Hubei Province has included the clinically diagnosed cases into the confirmed cases to be published starting from February 12, 2020. Clinically diagnosed cases are confirmed by a combination of travel history, symptoms and CT image rather than the virus lab test. So there are 14,840 new confirmed cases (including 13,332 clinically diagnosed cases) in Hubei province was reported in February 12, 2020, abided by the diagnosis and treatment scheme for the new coronavirus infections (pilot version 5) [17]. In this case, our CFR estimated will decrease due to the update of diagnosis standard. Furthermore, the distribution of patients between cure and death will totally different with that before February 12, 2020. Obviously, it is why our study period ended at February 11, 2020.

The competing risk model, for estimating the CFR in the early stage of COVID-19 epidemic, is applicable to any disease for which the final outcome is not known for a proportion of patients [20]. Using published daily summary data when individual data

is not available, provides a powerful sample to estimate CFR and to predict the future trend of disease epidemic.

Nevertheless, several limitations should be considered. First, our analyses were based on public summary data with a lack of individual level of time to death or cure, characteristics at baseline, such as age, gender and chronic disease status. Therefore, the heterogeneity of CFR among the subgroups is not able to be investigated. Neither is it easy to find the most susceptible population of COVID-19 to whom better protections should be provided. However, previous studies have found that males older than 65 years with multiple comorbidities such as cardiovascular diseases are the most vulnerable population than others, suffering with both the highest incidence of confirmed patients and the highest CFR [8-10]. Second, currently in our study, it is difficult to adjust the influence of the lag of the real case numbers resulting from insufficient medical resources in Hubei Province. With the development of the epidemic, this lag will be alleviated and then we can get a more precise idea of the severity of this COVID-19 epidemic.

Conclusion

Based on analyses of public data, we found that the adjusted CFR in Hubei was much higher than that of other regions in China (14.97% vs. 0.53%), over 20 times in all estimation. The CFR would follow a downwards trend based on our estimation and recently released data. Nevertheless, at early stage of outbreak, CFR estimates should

be viewed cautiously because of limited data source on true onset and recovery time.

References

1. Zhu, N., et al., *A Novel Coronavirus from Patients with Pneumonia in China, 2019*. N Engl J Med, 2020. DOI: 10.1056/NEJMoa2001017.

2. Lu, R., et al., *Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding*. Lancet, 2020. DOI: 10.1016/s0140-6736(20)30251-8.

3. Wu, F., et al., *A new coronavirus associated with human respiratory disease in China*. Nature, 2020. DOI: 10.1038/s41586-020-2008-3.

4. News, I. *SARS CoV-2 (formerly known as 2019-nCoV, or "Wuhan Coronavirus") COVID-19 Outbreak*. Access on February 11, 2020. Available from: https://www.isar-icar.com/Coronavirus.

5. WHO. *Novel Coronavirus (2019-nCoV) SITUATION REPORT-5 25 JANUARY 2020*. Access on January 25, 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200125-sitrep-5-2019-ncov.pdf?sfvrsn=429b143d_4.2020.

6. News, B. *Coronavirus disease named Covid-19*. Access on February 11, 2020. Available from: https://www.bbc.com/news/world-asia-china-51466362.

7. Phan, L.T., et al., *Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam*. N Engl J Med, 2020. DOI: 10.1056/NEJMc2001272.

8. Wang, D., et al., *Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China*. JAMA, 2020. DOI: 10.1001/jama.2020.1585.

9. Chen, N., et al., *Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study*. Lancet, 2020. DOI: 10.1016/s0140-6736(20)30211-7.

10. Huang, C., et al., *Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China*. Lancet, 2020. DOI: 10.1016/s0140-6736(20)30183-5.

11. Wu, J.T., K. Leung, and G.M. Leung, *Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study*. Lancet, 2020. DOI: 10.1016/s0140-6736(20)30260-9.

12. Li, Q., et al., *Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia*. N Engl J Med, 2020. DOI: 10.1056/NEJMoa2001316.

13. Battegay, M., et al., *2019-novel Coronavirus (2019-nCoV): estimating the case fatality rate - a word of caution*. Swiss Med Wkly, 2020. **150**: p. w20203. DOI: 10.4414/smw.2020.20203.

14. China, N.H.C.P.R. *Outbreak Communication*. Access on February 12, 2020. Available from: http://www.nhc.gov.cn/xcs/yqtb/202002/395f075a5f3a411f80335766c65b0487.shtml.

15. Marubini E, V.M., *Analysing Survival Data from Clinical Trials and Observational Studies*. 2004.

16. Chen, Z. and T. Nakamura, *Statistical evidence for the usefulness of Chinese medicine in the treatment of SARS*. Phytother Res, 2004. **18**(7): p. 592-4. DOI: 10.1002/ptr.1485.

17. China, N.H.C.P.R. *The diagnosis and treatment scheme for the new coronavirus infections*

(pilot version 5). Access on February 8, 2020. Available from:
http://www.nhc.gov.cn/xcs/zhengcwj/202002/d4b895337e19445f8d728fcaf1e3e13a/files/ab
6bec7f93e64e7f998d802991203cd6.pdf.

18. Wang, C., et al., *A novel coronavirus outbreak of global health concern.* Lancet, 2020. DOI: 10.1016/s0140-6736(20)30185-9.

19. Ilaria Dorigatti, L.O. *Report 4: Severity of 2019-novel coronavirus (nCoV).* Access on February 10, 2020. Available from:
https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-fellowships/Impe
rial-College-2019-nCoV-severity-10-02-2020.pdf.

20. Ghani, A.C., et al., *Methods for estimating the case fatality ratio for a novel, emerging infectious disease.* Am J Epidemiol, 2005. **162**(5): p. 479-86. DOI: 10.1093/aje/kwi230.

21. *Wuhan Headquarters of Epidemic Prevention and Control of 2019-nCov Pneumonia: Notice of Epidemic Prevention and Control of 2019-nCov Pneumonia (No. 1).* Access on January 23, 2020. Available from:
http://www.wuhan.gov.cn/hbgovinfo/zwgk_8265/tzgg/202001/t20200123_304065.html.

Table 1. Dates of slope change and dates (in yellow) used for CFR estimation

Date	China, moving the date of cure backward for (days)				Hubei, moving the date of cure backward for (days)				Other provinces, moving the date of cure backward for（days）			
	0	3	5	7	0	3	5	7	0	3	5	7
1.20												
1.21												
1.22												
1.23								JP 1				
1.24		JP 1										
1.25												
1.26			JP 1				JP 1					
1.27	JP 1			JP 1	JP 1	JP 1				JP 1		
1.28											JP 1	JP 1
1.29		JP 2							JP 1			
1.30										JP 2		
1.31			JP 2									
2.01	JP 2				JP 2		JP 2					
2.02		JP 3										
2.03						JP 2						
2.04												
2.05	JP 3											
2.06					JP 3							
2.07												
2.08												
2.09												
2.10												
2.11												

JP：Joinpoint. JPs in the table represents that the slope of linear fitting changes on that day. In all cases, the slope changes up to three times. Due to the backward migration of cure data, there is no corresponding death and diagnosis data within the corresponding 3, 5 and 7 days, therefore the last day for the estimation of fatality rate will be February 11th minus the corresponding moved backward days.

Table 2. Adjusted CFR estimation assuming an average period of observation

stays for 3-7 days after recovery

Moving the date of cure backward for	0 days	3 days	5 days	7 days
China (%, 95%CI)	13.4(12.80-14.04)	11.2(10.62-11.81)	9.54(9.39-9.92)	8.91(8.33-9.52)
Hubei (%, 95%CI)	19.61(18.94-20.33)	16.23(15.63-16.86)	14.97(14.22-15.77)	12.72(12.48-12.97)
Other provinces (%, 95%CI)	1.88(1.73-2.06)	1.08(0.89-1.34)	0.52(0.42-0.71)	0.32(0.25-0.48)

Fig.1 Cumulative number of deaths in Hubei and other provinces

Fig.2 Cumulative number of cures in Hubei and other provinces

Fig.3 Joinpoint regression of cumulative cured hazard vs. cumulative death hazard in Hubei

Fig.4 Joinpoint regression of cumulative cured hazard vs. cumulative death hazard in other provinces

Fig. 5 Joinpoint regression with moving the date of cure backward for 3, 5, 7 days in Hubei

Fig. 6 Joinpoint regression with moving the date of cure backward for 3, 5, 7 days in other provinces

Fig. 7 The adjusted 5 days after recovery CFR of COVID-19 during different time periods in Hubei and other provinces